Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293211 | 0.88 | CYP1A2 (0.39) | — | |
| SCHEMBL294406 | 0.86 | CYP1A2 (0.33) | NOS1NOS2 | |
| SCHEMBL293603 | 0.84 | ALDH1A1 (0.35) | NOS1NOS2 | |
| SCHEMBL292746 | 0.82 | — | — | |
| SCHEMBL3021461 | 0.78 | — | — | |
| SCHEMBL12663108 | 0.76 | — | — | |
| SCHEMBL15373079 | 0.76 | — | — | |
| SCHEMBL15373069 | 0.76 | — | — | |
| SCHEMBL9342939 | 0.76 | FYN (0.32) | FYN | |
| SCHEMBL28840626 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086538-B1 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING DIMEBON AND DONEPEZIL | MEDIVATION NEUROLOGY INC (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2420235-A1 | Methods and combination therapies for treating alzheimer's disease | Medivation Neurology, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | MEDIVATION NEUROLOGY, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100099714-A1 | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2086538-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I.A. DIMEBON AND DOLEPEZIL | Medivation Neurology, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008051599-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I. A. DIMEBON AND DOLEPEZIL | MEDIVATION NEUROLOGY, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | NOS3 305/4885NOS1 185/4885NOS2 214/4885 |
| US-20100099714-A1 | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases | GRIN1, GRIN2A, GRIN3A | NOS3 1266/4885NOS1 845/4885NOS2 1267/4885 |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | PSEN2, APP, PSEN1 | NOS3 118/4885NOS1 295/4885NOS2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.